Skip to main content

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices traded up today with the

Dow Jones Industrial Average

(

^DJI

) trading up 140 points (0.8%) at 17,869 as of Tuesday, Feb. 10, 2015, 4:20 PM ET. The NYSE advances/declines ratio sits at 1,747 issues advancing vs. 1,330 declining with 126 unchanged.

The Drugs industry as a whole closed the day up 1.2% versus the S&P 500, which was up 1.1%. Top gainers within the Drugs industry included

Oragenics

(

OGEN

), up 3.9%,

Aoxing Pharmaceutical

(

AXN

), up 8.4%,

ImmuCell

TheStreet Recommends

(

ICCC

), up 2.1%,

Merus Labs International

(

MSLI

), up 1.7% and

Tianyin Pharmaceutical

(

TPI

), up 3.7%.

TheStreet Ratings Group would like to highlight 3 stocks pushing the industry higher today:

Merus Labs International

(

MSLI

) is one of the companies that pushed the Drugs industry higher today. Merus Labs International was up $0.03 (1.7%) to $1.75 on average volume. Throughout the day, 25,451 shares of Merus Labs International exchanged hands as compared to its average daily volume of 24,400 shares. The stock ranged in a price between $1.72-$1.82 after having opened the day at $1.73 as compared to the previous trading day's close of $1.72.

Merus Labs International Inc., a specialty pharmaceutical company, engages in the acquisition and licensing of prescription medicines in the United States, Canada, and Europe. Merus Labs International has a market cap of $137.3 million and is part of the health care sector. Shares are up 4.1% year-to-date as of the close of trading on Monday. Currently there are no analysts who rate Merus Labs International a buy, no analysts rate it a sell, and none rate it a hold.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

TheStreet Ratings rates Merus Labs International as a

sell

. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income, disappointing return on equity and weak operating cash flow.

Highlights from TheStreet Ratings analysis on MSLI go as follows:

  • MERUS LABS INTERNATIONAL INC has experienced a steep decline in earnings per share in the most recent quarter in comparison to its performance from the same quarter a year ago. The company has suffered a declining pattern earnings per share over the past two years. During the past fiscal year, MERUS LABS INTERNATIONAL INC reported poor results of -$0.16 versus -$0.05 in the prior year.
  • The company, on the basis of change in net income from the same quarter one year ago, has significantly underperformed when compared to that of the S&P 500 and the Pharmaceuticals industry. The net income has significantly decreased by 8483.0% when compared to the same quarter one year ago, falling from -$0.05 million to -$4.55 million.
  • The company's current return on equity has slightly decreased from the same quarter one year prior. This implies a minor weakness in the organization. Compared to other companies in the Pharmaceuticals industry and the overall market, MERUS LABS INTERNATIONAL INC's return on equity significantly trails that of both the industry average and the S&P 500.
  • Net operating cash flow has decreased to $3.47 million or 19.13% when compared to the same quarter last year. Despite a decrease in cash flow MERUS LABS INTERNATIONAL INC is still fairing well by exceeding its industry average cash flow growth rate of -55.25%.
  • MSLI, with its decline in revenue, underperformed when compared the industry average of 15.1%. Since the same quarter one year prior, revenues fell by 34.1%. The declining revenue appears to have seeped down to the company's bottom line, decreasing earnings per share.

You can view the full analysis from the report here:

Merus Labs International Ratings Report

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

At the close,

Aoxing Pharmaceutical

(

AXN

) was up $0.04 (8.4%) to $0.57 on heavy volume. Throughout the day, 133,299 shares of Aoxing Pharmaceutical exchanged hands as compared to its average daily volume of 50,300 shares. The stock ranged in a price between $0.55-$0.60 after having opened the day at $0.59 as compared to the previous trading day's close of $0.53.

Aoxing Pharmaceutical Company, Inc., a specialty pharmaceutical company, researches, develops, manufactures, and distributes various narcotic, pain-management, and addiction treatment pharmaceutical products primarily in the People's Republic of China. Aoxing Pharmaceutical has a market cap of $30.4 million and is part of the health care sector. Shares are up 44.7% year-to-date as of the close of trading on Monday. Currently there are no analysts who rate Aoxing Pharmaceutical a buy, no analysts rate it a sell, and none rate it a hold.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

TheStreet Ratings rates Aoxing Pharmaceutical as a

sell

. The company's weaknesses can be seen in multiple areas, such as its generally high debt management risk and weak operating cash flow.

Highlights from TheStreet Ratings analysis on AXN go as follows:

  • The debt-to-equity ratio is very high at 14.68 and currently higher than the industry average, implying increased risk associated with the management of debt levels within the company. Along with this, the company manages to maintain a quick ratio of 0.19, which clearly demonstrates the inability to cover short-term cash needs.
  • Net operating cash flow has declined marginally to -$2.29 million or 2.78% when compared to the same quarter last year. Despite a decrease in cash flow of 2.78%, AOXING PHARMACEUTICAL CO INC is still significantly exceeding the industry average of -55.25%.
  • The company's current return on equity greatly increased when compared to its ROE from the same quarter one year prior. This is a signal of significant strength within the corporation. Compared to other companies in the Pharmaceuticals industry and the overall market, AOXING PHARMACEUTICAL CO INC's return on equity significantly trails that of both the industry average and the S&P 500.
  • The gross profit margin for AOXING PHARMACEUTICAL CO INC is currently very high, coming in at 72.68%. It has increased significantly from the same period last year. Regardless of the strong results of the gross profit margin, the net profit margin of -0.17% is in-line with the industry average.
  • This stock has increased by 66.66% over the past year, outperforming the rise in the S&P 500 Index during the same period. Regarding the future course of this stock, we feel that the risks involved in investing in AXN do not compensate for any future upside potential, despite the fact that it has seen nice gains over the past 12 months.

You can view the full analysis from the report here:

Aoxing Pharmaceutical Ratings Report

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Oragenics

(

OGEN

) was another company that pushed the Drugs industry higher today. Oragenics was up $0.03 (3.9%) to $0.74 on light volume. Throughout the day, 16,165 shares of Oragenics exchanged hands as compared to its average daily volume of 35,600 shares. The stock ranged in a price between $0.70-$0.79 after having opened the day at $0.77 as compared to the previous trading day's close of $0.72.

Oragenics, Inc. focuses on the discovery, development, and commercialization of various technologies associated with oral health, antibiotics, and other general health benefits. Oragenics has a market cap of $27.6 million and is part of the health care sector. Shares are down 14.2% year-to-date as of the close of trading on Monday. Currently there are no analysts who rate Oragenics a buy, no analysts rate it a sell, and 1 rates it a hold.

TheStreet Ratings rates Oragenics as a

sell

. Among the areas we feel are negative, one of the most important has been a generally disappointing historical performance in the stock itself.

Highlights from TheStreet Ratings analysis on OGEN go as follows:

  • OGEN's stock share price has done very poorly compared to where it was a year ago: Despite any rallies, the net result is that it is down by 76.90%, which is also worse that the performance of the S&P 500 Index. Investors have so far failed to pay much attention to the earnings improvements the company has managed to achieve over the last quarter. Naturally, the overall market trend is bound to be a significant factor. However, in one sense, the stock's sharp decline last year is a positive for future investors, making it cheaper (in proportion to its earnings over the past year) than most other stocks in its industry. But due to other concerns, we feel the stock is still not a good buy right now.
  • The company, on the basis of net income growth from the same quarter one year ago, has significantly underperformed compared to the Biotechnology industry average, but is greater than that of the S&P 500. The net income increased by 89.0% when compared to the same quarter one year prior, rising from -$9.33 million to -$1.03 million.
  • The company's current return on equity greatly increased when compared to its ROE from the same quarter one year prior. This is a signal of significant strength within the corporation. Compared to other companies in the Biotechnology industry and the overall market, ORAGENICS INC's return on equity significantly trails that of both the industry average and the S&P 500.
  • The revenue fell significantly faster than the industry average of 41.5%. Since the same quarter one year prior, revenues fell by 20.6%. The declining revenue has not hurt the company's bottom line, with increasing earnings per share.
  • The gross profit margin for ORAGENICS INC is rather high; currently it is at 66.67%. It has increased from the same quarter the previous year. Regardless of the strong results of the gross profit margin, the net profit margin of -512.43% is in-line with the industry average.

You can view the full analysis from the report here:

Oragenics Ratings Report

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.